“We use cookies on this website to enhance your user experience and to personalise content. By clicking any link or continuing to use our Website you agree to our cookies as per our Privacy Policy. Read More” Ok, I agree

Insulin Glargine And Lixisenatide (Soliqua 100/33)

Trade Name : Soliqua 100/33

Sanofi-Aventis U.S. LLC

INJECTION, SOLUTION

Strength 10033 U/mLug/mL

INSULIN GLARGINE; LIXISENATIDE Insulin [Chemical/Ingredient],Insulin Analog [EPC],GLP-1 Receptor Agonist [EPC],Glucagon-Like Peptide 1 [CS],Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]

Delivery Process

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

We’ll Get in Touch

Once we review your request, we’ll send you an estimated price for the medicine within 2-5 days.

Confirmation and Payment

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Product information is meant for

Wholesalers Suppliers Exporters Doctors MOH Tender Supplies Hospitals Brand CROs Comparator Supplies Generic Cooperate Sourcing Individual Patients Indian Institutional Buyers

Disclaimer

Trade Marks displayed in compliance with provisions of: Trademark Act, 1999 u/s 30 and 30 (1) of "Fair use"

GNH India is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler/ Supplier/ Exporters/ Importer from India of Insulin Glargine And Lixisenatide (Soliqua 100/33) which is also known as Soliqua 100/33 and Manufactured by Sanofi-Aventis U.S. LLC. It is available in strength of 100; 33 U/mL; ug/mL per ml. Read more

Insulin Glargine And Lixisenatide (Soliqua 100/33) is supplied for Tenders/ Emergency imports/ Un - licensed, Specials, Orphan drug/ Name patient line/ RLD supplies/ Reference listed drugs/ Comparator Drug/ Bio-Similar/ Innovator samples For Clinical trials.  Click to know price.     Read less

Packaging and Delivery

Validated Cold Chain Shipment

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Inquire directly from our website and get 5% off on any medicine!

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more

About GNH

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more
  • No data
  • No data
  • SOLIQUA 100/33 is a combination of insulin glargine and lixisenatide and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
  • Limitations of Use
  • SOLIQUA 100/33 is a combination of a long-acting human insulin analog with a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ()
  • 1
  • Has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.
  • Not recommended for use in combination with any other product containing a GLP-1 receptor agonist.
  • Not for treatment of type 1 diabetes mellitus or diabetic ketoacidosis.
  • Not recommended for use in patients with gastroparesis.
  • Has not been studied in combination with prandial insulin.
  • No data
  • Inject subcutaneously once a day within the hour prior to the first meal of the day. ()
  • SOLIQUA 100/33 pen delivers 15 units to 60 units per injection. (, )
  • Maximum daily dosage is 60 units (60 units of insulin glargine and 20 mcg of lixisenatide). ()
  • Discontinue basal insulin or GLP-1 receptor agonist prior to initiation. ()
  • In patients naive to basal insulin or to a GLP-1 receptor agonist, currently on less than 30 units of basal insulin, or on a GLP-1 receptor agonist, the recommended starting dosage is 15 units subcutaneously once daily. ()
  • In patients inadequately controlled on 30 to 60 units of basal insulin, the starting dosage is 30 units subcutaneously once daily. ()
  • See Full Prescribing Information for titration recommendations. ()
  • Inject subcutaneously in abdominal area, thigh, or upper arm and rotate injection sites within the same region from one injection to the next to reduce risk of lipodystrophy and localized cutaneous amyloidosis. ()
  • Do not administer intravenously, intramuscularly, or by an infusion pump. ()
  • Do not dilute or mix with any other insulin products or solutions. ()
  • SOLIQUA 100/33 injection: 100 units insulin glargine per mL and 33 mcg lixisenatide per mL is available as a clear, colorless to almost colorless solution in a 3 mL prefilled, disposable, single-patient-use SoloStar pen.
  • Injection: 100 units of insulin glargine per mL and 33 mcg of lixisenatide per mL in a 3 mL single-patient-use pen. ()
  • SOLIQUA 100/33 is contraindicated:
  • During episodes of hypoglycemia. ()
  • Hypersensitivity to SOLIQUA 100/33 either of the active drug substances (insulin glargine or lixisenatide), or any of its excipients. Hypersensitivity reactions including anaphylaxis have occurred with both lixisenatide and insulin glargine. ()
  • No data
  • Anaphylaxis and serious hypersensitivity reactions
  • Pancreatitis
  • Never share
  • Hyperglycemia or hypoglycemia with changes in insulin regimen
  • Overdose due to medication errors
  • Hypoglycemia
  • Acute kidney injury
  • Immunogenicity
  • Hypokalemia
  • Fluid retention and heart failure with use of thiazolidinediones (TZDs)
  • Macrovascular outcomes
  • The following adverse reactions are discussed elsewhere:
  • The most common adverse reactions, reported in u22655% of patients treated with SOLIQUA 100/33 include hypoglycemia, nausea, nasopharyngitis, diarrhea, upper respiratory tract infection, and headache. ()
  • To report SUSPECTED ADVERSE REACTIONS, contact sanofi-aventis at 1-800-633-1610 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatchn
  • No data
  • Drugs that affect glucose metabolism
  • Antiadrenergic Drugs
  • Effects of delayed gastric emptying on oral medications
  • No data
  • Pregnancy
  • 8.1
  • No data
  • SOLIQUA 100/33 (insulin glargine and lixisenatide injection), for subcutaneous use, is a combination of a long-acting basal insulin analog, insulin glargine, and a GLP-1 receptor agonist, lixisenatide.
  • Each SOLIQUA 100/33 prefilled single-patient-use disposable pen contains 300 units of insulin glargine and 100 mcg of lixisenatide in 3 mL of a clear, colorless to almost colorless, sterile, and aqueous solution. Each mL of solution contains 100 units insulin glargine and 33 mcg lixisenatide.
  • SOLIQUA 100/33 contains the following inactive ingredients (per mL): 3 mg of methionine, 2.7 mg of metacresol, 20 mg of glycerol, 30 mcg of zinc, hydrochloric acid, sodium hydroxide and water for injection.
  • No data
  • No data
  • No data
  • No data
  • Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).
  • sanofi-aventis U.S. LLCBridgewater, NJ 08807A SANOFI COMPANY
  • u00a92019 sanofi-aventis U.S. LLC
  • SOLIQUA and SoloStar are registered trademarks of sanofi-aventis U.S. LLC.
  • No data
  • Read these instructions carefully before using your SOLIQUA 100/33 pen.
  • Do not share your SOLIQUA 100/33 pen with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.
  • SOLIQUA 100/33 is an injectable prescription medicine that contains 2 diabetes medicines, insulin glargine and lixisenatide in a SoloStar pen. The drug combination in this pen is only for the daily injection of 15 to 60 units of SOLIQUA 100/33. Each unit dialed contains 1 unit insulin glargine and 0.33 mcg lixisenatide.
  • Important information
  • Learn to inject
  • Need help?
  • If you have any questions about your pen or about diabetes, ask your healthcare provider, go to or call sanofi-aventis at .
  • Supplies you will need:
  • Places to inject
  • Get to know your pen
  • Step 1: Check your pen
  • Take a new pen out of the refrigerator at least 1 hour before you inject.
  • If you have other injector pens
  • Step 2: Attach a new needle
  • Handling needles
  • Step 3: Do a safety test
  • Perform a safety test before each injection to:
  • If no liquid appears:
  • If you see air bubbles
  • Step 4: Select the dose
  • How to read the dose window
  • Units of medicine in your pen
  • Step 5: Inject your dose
  • If you find it hard to press the injection button in, force it as this may break your pen. See the section after Step 5E below for help.
  • If you find it hard to press the injection button in:
  • Step 6: Remove the needle
  • Use by
  • How to store your pen
  • Before first use
  • After first use
  • Keep this pen out of the sight and reach of children.
  • How to care for your pen
  • Handle your pen with care
  • Protect your pen from dust and dirt
  • Throwing your pen away
  • This Instructions for Use has been approved by the U.S. Food and Drug Administration.
  • Revised: November 2019
  • sanofi-aventis U.S. LLCBridgewater, NJ 08807A SANOFI COMPANY
  • u00a9 2019 sanofi-aventis U.S. LLC
  • SOLIQUA and SoloStar are registered trademarks of sanofi-aventis U.S. LLC.
  • NDC 0024-5761-05Rx ONLY
  • SOLIQUA 100/33(insulin glargine and lixisenatide injection)For Single Patient Use Only100 units/mL and 33 mcg/mLWith each unit of insulin glargine,the pen also delivers 0.33 mcg of lixisenatideOnly for Doses from 15 to 60 Units
  • Solution for injection in a SoloStar disposable insulin delivery deviceNever remove medication using a syringeDo not mix with other insulinsFor subcutaneous injection onlyUse only if solution is clear and colorless with no particles visible
  • *Needles not included (see back panel)Five 3 mL prefilled pens (15 mL total) u2013 Dispense in this sealed cartonDispense with the medication guide
  • SANOFI

Similar Products

Desogestrel And Ethinyl Estradiol (Emoquette)

Desogestrel And Ethinyl Estradiol (Emoquette)

Manufacturer: REMEDYREPACK INC.

Presentation: KIT

Strength:

Pack Size:

Diphenoxylate Hydrochloride And Atropine Sulfate (Diphenoxylate Hydrochloride And Atropine Sulfate)

Diphenoxylate Hydrochloride And Atropine Sulfate (Diphenoxylate Hydrochloride And Atropine Sulfate)

Manufacturer: REMEDYREPACK INC.

Presentation: TABLET

Strength: 2.5; .025 mg/1; mg/1

Pack Size:

Fluoxetine Hydrochloride (Fluoxetine)

Fluoxetine Hydrochloride (Fluoxetine)

Manufacturer: REMEDYREPACK INC.

Presentation: CAPSULE

Strength: 40 mg/1

Pack Size:

Metoprolol Succinate (Metoprolol Succinate)

Metoprolol Succinate (Metoprolol Succinate)

Manufacturer: REMEDYREPACK INC.

Presentation: TABLET, EXTENDED RELEASE

Strength: 25 mg/1

Pack Size:

Losartan Potassium (Losartan Potassium)

Losartan Potassium (Losartan Potassium)

Manufacturer: REMEDYREPACK INC.

Presentation: TABLET, FILM COATED

Strength: 25 mg/1

Pack Size:

Browse Our Services And Processes

Comparator Sourcing for Clinical Trials

Comparator Sourcing for Clinical Trials

GNH India brings over 10 years of experience in Comparator

Read More

Name Patient Supply

Name Patient Supply

Today, the exact cause for many rare diseases remains unknown

Read More

Validated Cold Chain Shipment

Validated Cold Chain Shipment

With shifting of pharma industry from synthetic molecules to biologic

Read More

Clinical Trials Supply

Clinical Trials Supply

STOP SOURCING..... START SMART SOURCING...... COME STRAIGHT TO THE SOURCE

Read More

Pharmaceutical Contract Manufacturing

Pharmaceutical Contract Manufacturing

GNH Provides Contract Manufacturing services for: Generic Medicines with following

Read More

Pricing

Pricing

PRICING POLICY Terms of sales are typically prepaid, unless otherwise

Read More

Disclaimer

Please see the Legal Notice for detailed terms and disclaimers. The Legal Notice governs the use of this Website and by accessing and using this Website you agree to be bound by and accept the Legal Notice.

Browse from other international pharmaceuticals

General

64020 Products

GNH India Brings to over 64036 Product SKUs from India all at 1 place with easy access and global deliveries.

US NDC

71247 Products

GNH India Brings to over 71252 Product SKUs from India all at 1 place with easy access and global deliveries.

Canadian DIN

51046 Products

GNH India Brings to over 51047 Product SKUs from India all at 1 place with easy access and global deliveries.

Swiss Drugs

150 Products

GNH India Brings to over 150 Product SKUs from India all at 1 place with easy access and global deliveries.

NZ Drugs

13296 Products

GNH Brings to over 13298 Product SKUs from India all at 1 place with easy access and global deliveries.

FAQ

Check out our delivery process

Can’t find what
you’re looking for?

Contact US
Get Price

Are you an existing customer or a vendor of GNH India? Log in here to

View your Transaction
COMPANY
SERVICES
QUICK LINKS
CONTACT US
Registered Office Address:

Unit # G- 14, 15, 16, 17, Ground Floor, Prabhadevi Industrial Estate, Enterprises Industrial Premises, 408, Veer Sawarkar Road, Prabhadevi,
Mumbai 400025 India

US Office Address:

GNH Pharmaceuticals USA LLC,
Suite E # 499, 1235 EAST BLVD,
Charlotte, NC, 28203, U.S.A
TEL: +1 704 557 0412

Pharmexcil
DB
FIEO-2016
SiteLock

Copyright © 2024 GNHIndia .com. All Rights Reserved. Please read Legal Notice for further details.

Disclaimer: Product names, logos, brands and other trademarks featured or referred to are the property of their respective trademark holders.